PIK3CA and breast cancer: Given the clinically meaningful results of the PI3K inhibitors in PIK3CA-mutated metastatic BC patients [8, 9], the reliable detection of PIK3CA mutations remains of outmost importance as it could guide physicians’ choices (level of evidence I-A according to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) score) [37].